Sept 29 (Reuters) - Mirum Pharmaceuticals Inc said on Wednesday that the U.S. Food and Drug Administration has approved its drug to treat itching in patients with Alagille syndrome, making it the first approved therapy for treating symptoms of the genetic disorder. (Reporting by Mrinalika Roy and Bhanvi Satija in Bengaluru; Editing by Shinjini Ganguli)
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
24.59 USD | +1.74% | +2.42% | -16.70% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.70% | 1.14B | |
+3.14% | 42.11B | |
+48.83% | 40.08B | |
+8.44% | 40B | |
-10.82% | 26.87B | |
+8.21% | 24.58B | |
-22.98% | 18.44B | |
+1.48% | 11.94B | |
+33.21% | 11.66B | |
+7.01% | 11.01B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- Mirum Pharmaceuticals : FDA approves Mirum Pharma's drug for itching associated with rare liver disorder